

09/787,866

(FILE 'HOME' ENTERED AT 22:53:25 ON 04 SEP 2003)

FILE 'REGISTRY' ENTERED AT 22:53:50 ON 04 SEP 2003
E TETRACYCLINE/CN

L1 1 S E3
E MINOCYCLINE/CN
L2 2 S E2-E5
E DOXYCYCLINE/CN
L3 1 S E3

FILE 'HCAPLUS' ENTERED AT 22:55:27 ON 04 SEP 2003
L4 3 S (L1 OR L2 OR L3) (P)CATARACT?

FILE 'STNGUIDE' ENTERED AT 23:01:22 ON 04 SEP 2003

FILE 'HCAPLUS' ENTERED AT 23:13:58 ON 04 SEP 2003
L5 82 S (DEDIMETHYL(2A)AMINO(2A)TETRACYCLIN? OR DEDIMETHYLAMINOTETRAC
L6 1 S (DEDIMETHYL(2A)AMINO(2A)TETRACYCLIN? OR DEDIMETHYLAMINOTETRAC

09/787,866

=> s (l1 or l2 or l3) (p)cataract?
13549 L1
1984 L2
3005 L3
6826 CATARACT?
L4 3 (L1 OR L2 OR L3) (P)CATARACT?

=> d 14 abs ibib kwic hitrn 1-3

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
AB Methods of reducing the risk of cataract development in a mammal are provided and include administering to the mammal an effective amt. of a tetracycline deriv. A preferred tetracycline deriv. is 6.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline.

ACCESSION NUMBER: 2000:227458 HCAPLUS
DOCUMENT NUMBER: 132:260702
TITLE: Tetracycline derivatives for inhibition of cataract formation
INVENTOR(S): Ryan, Maria Emanuel; Golub, Lorne M.; Ramamurthy, Nungavaram S.
PATENT ASSIGNEE(S): The Research Foundation of State University of New York, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20000018353	A2	20000406	WO 1999-US22354	19990928
WO 20000018353	A3	20000706		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2343038	AA	20000406	CA 1999-2343038	19990928
EP 1124558	A2	20010822	EP 1999-949910	19990928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525299	T2	20020813	JP 2000-571875	19990928
AU 759372	B2	20030410	AU 1999-62684	19990928
PRIORITY APPLN. INFO.:			US 1998-102056P P	19980928
			WO 1999-US22354 W	19990928

OTHER SOURCE(S): MARPAT 132:260702
IT 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs.
564-25-0 2444-65-7, CMT-1 2444-65-7D, derivs. 4199-33-1,
CMT-2 4199-36-4 4199-36-4D, derivs. 4632-89-7, CMT-4
10118-90-8, Minocycline 15866-90-7, CMT-3 27720-34-9, CMT 6
36391-64-7, CMT-7 52749-95-8 88828-25-5, CMT-8 130640-55-0

137453-88-4 137453-91-9 145031-44-3, CMT 5 180002-76-0, CMT-10
 209742-23-4, CMT-9 249888-78-6 263258-24-8 263258-25-9 263258-26-0
 263258-27-1 263258-27-1D, acyl derivs. 263258-28-2 263258-29-3
 263258-30-6 263258-30-6D, acyl derivs. 263258-31-7D, acyl derivs.
 263258-32-8 263258-33-9 263258-34-0 263258-35-1 263258-36-2
 263258-37-3 263258-37-3D, acyl derivs. 263258-38-4 263258-39-5
 263258-39-5D, acyl and monoalkyl derivs. 263258-40-8 263258-40-8D,
 acyl derivs. 263258-41-9 263258-42-0 263258-43-1 263258-44-2
 263258-45-3 263258-45-3D, acyl derivs. 263258-46-4 263258-47-5
 263258-48-6 263258-48-6D, acyl derivs. 263258-49-7D, acyl derivs.
 263258-50-0 263258-51-1 263258-52-2 263258-53-3 263258-54-4
 263258-55-5 263258-56-6 263258-57-7 263258-58-8 263258-59-9
 263258-59-9D, acyl and monoalkyl derivs. 263258-60-2 263258-61-3
 263258-61-3D, acyl derivs. 263258-62-4 263258-63-5 263258-64-6
 263258-65-7 263258-65-7D, acyl derivs. 263258-66-8 263258-67-9
 263258-68-0 263258-68-0D, acyl derivs. 263258-69-1D, acyl derivs.
 263258-70-4 263258-71-5 263258-72-6 263258-73-7 263258-74-8
 263258-75-9 263258-76-0 263258-77-1 263258-78-2 263258-79-3
 263258-79-3D, acyl and monoalkyl derivs. 263258-80-6 263258-81-7
 263258-81-7D, acyl derivs. 263258-82-8 263258-83-9 263258-84-0
 263258-85-1 263258-85-1D, acyl derivs. 263258-86-2 263258-87-3
 263258-88-4 263258-88-4D, acyl derivs. 263258-89-5D, acyl derivs.
 263258-90-8 263258-91-9 263258-92-0 263258-93-1 263258-94-2
 263258-95-3 263258-96-4 263258-97-5 263258-98-6 263258-99-7
 263258-99-7D, acyl and monoalkyl derivs. 263259-00-3 263259-01-4
 263259-01-4D, acyl derivs. 263259-02-5 263259-03-6 263259-04-7
 263259-05-8 263259-05-8D, acyl derivs. 263259-06-9 263259-07-0
 263259-08-1 263259-08-1D, acyl derivs. 263259-09-2D, acyl derivs.
 263259-10-5 263259-11-6 263259-12-7 263259-13-8 263259-14-9
 263259-15-0 263259-16-1 263259-17-2 263259-18-3 263259-19-4
 263259-19-4D, acyl and monoalkyl derivs. 263259-20-7 263259-21-8
 263259-21-8D, acyl derivs. 263259-22-9 263259-23-0 263259-23-0D,
 acyl derivs. 263259-24-1 263259-26-3 263259-27-4 263259-28-5
 263259-28-5D, acyl derivs. 263259-29-6 263259-30-9 263259-31-0
 263259-32-1 263259-32-1D, acyl derivs. 263259-33-2 263259-34-3
 263259-35-4 263259-36-5 263259-37-6 263259-38-7 263259-39-8
 263259-40-1 263259-40-1D, acyl and monoalkyl derivs. 263259-41-2
 263259-42-3 263259-42-3D, acyl derivs. 263259-43-4 263259-44-5
 263259-44-5D, acyl derivs. 263259-45-6 263259-46-7 263259-47-8
 263259-48-9 263259-48-9D, acyl derivs. 263259-49-0 263259-50-3
 263259-51-4 263259-52-5 263259-52-5D, acyl derivs. 263259-53-6
 263259-54-7 263259-55-8 263259-56-9 263259-57-0 263259-58-1
 263259-59-2 263259-60-5 263259-60-5D, acyl and monoalkyl derivs.
 263259-61-6 263259-62-7 263259-62-7D, acyl derivs. 263259-63-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline derivs. for inhibition of cataract formation)

IT 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs.

564-25-0 10118-90-8, Minocycline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline derivs. for inhibition of cataract formation)

L4 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2003 ACS on STN

AB Kynurenone derivs., harmone (.beta.-carboline), and tetracycline hydrochloride, known photosensitizers of cataractogenesis in lens,

09/787, 866

produced singlet O (102) under photoexcitation in air-satd. aq. (D2O) soln. The quantum yields of the 102 generation by these substances are detd. It is suggested that 102 might take part in cataractogenesis.

ACCESSION NUMBER: 1987:212011 HCPLUS
DOCUMENT NUMBER: 106:212011
TITLE: Photosensitized generation of singlet molecular oxygen by endogenous photosensitizers of the human lens
AUTHOR(S): Egorov, S. Yu.; Babizhaev, M. A.; Krasnovsky, A. A., Jr.; Shvedova, A. A.
CORPORATE SOURCE: Biol. Dep., M. V. Lomonosov Moscow State Univ., Moscow, USSR
SOURCE: Biofizika (1987), 32(1), 169-71
CODEN: BIOFAI; ISSN: 0006-3029
DOCUMENT TYPE: Journal
LANGUAGE: Russian
IT 60-54-8 343-65-7 484-78-6 492-27-3 108490-82-0
RL: BIOL (Biological study)
(singlet oxygen photosensitized generation induction by, of human eye lens, cataract formation in relation to)
IT 60-54-8
RL: BIOL (Biological study)
(singlet oxygen photosensitized generation induction by, of human eye lens, cataract formation in relation to)

L4 ANSWER 3 OF 3 HCPLUS COPYRIGHT 2003 ACS on STN
AB Application of lidase to burn-induced rabbit corneal cataracts decreased the no. of acid mucopolysaccharides formed. Collagenase treatment caused thinning and then disappearance of the fibrous structures. Visual activity increased in 6 of 8 rabbit eyes treated with lidase plus tetracycline [60-54-8] ointment. Collagenase plus tetracycline increased visual acuity in 57.5% of the eyes treated, but did not affect intraocular pressure or the field of vision.
ACCESSION NUMBER: 1972:30596 HCPLUS
DOCUMENT NUMBER: 76:30596
TITLE: Effectiveness of using lidase and collagenase for treating corneal opacity
AUTHOR(S): Smirnov, I. V.
CORPORATE SOURCE:
SOURCE: Makro- Mikrostrukt. Tkanei Norme, Patol. Eksp. (1969), 34-43. Editor(s): Gordon, D. S. Chuvash. Gos. Univ.: Cheboksary, USSR.
CODEN: 24APA3
DOCUMENT TYPE: Conference
LANGUAGE: Russian
AB Application of lidase to burn-induced rabbit corneal cataracts decreased the no. of acid mucopolysaccharides formed. Collagenase treatment caused thinning and then disappearance of the fibrous structures. Visual activity increased in 6 of 8 rabbit eyes treated with lidase plus tetracycline [60-54-8] ointment. Collagenase plus tetracycline increased visual acuity in 57.5% of the eyes treated, but did not affect intraocular pressure or. . .
IT 60-54-8
RL: BIOL (Biological study)
(in corneal cataract treatment with collagenase and lidase)
IT 60-54-8
RL: BIOL (Biological study)
(in corneal cataract treatment with collagenase and lidase)

09/787, 866

=>

Delacroix

09/787,866

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 60-54-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-
(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- (7CI, 8CI)
OTHER NAMES:
CN (-)-Tetracycline
CN Abramycin
CN Achromycin
CN Achromycin (naphthacene derivative)
CN Agromicina
CN Ambramicina
CN Ambramycin
CN Bio-Tetra
CN Biocycline
CN Ciclibion
CN Cyclomycin
CN Cytome
CN Deschlorobiomycin
CN Enterocycline
CN Limecycline
CN Medocycline
CN Mericycline
CN Micycline
CN Neocycline
CN NSC 108579
CN Omegamycin
CN Orlycycline
CN Panmycin
CN Polycycline
CN Polycycline (antibiotic)
CN Resteclin
CN Roviciclina
CN Sumycin syrup
CN Tetra-Co
CN Tetracycline
CN Tetradeclin
CN Tetrafil
CN Veracin
CN Vetacyclinum
FS STEREOSEARCH
DR 6591-49-7
MF C22 H24 N2 O8
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU,
EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT,

Delacroix

09/787,866


RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13508 REFERENCES IN FILE CA (1937 TO DATE)

687 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

13532 REFERENCES IN FILE CAPLUS (1937 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)